A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but ...

Researchers have discovered that tirzepatide and semaglutide impact energy metabolism in distinct ways. New animal research ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity ...

WeightWatchers teams up with UK weight-loss drug provider CheqUp in a major shift from its traditional dieting model, amid ...

The latest budget proposal to cut anti-obesity medication (AOM) coverage by Medi-Cal will cost the state more in the long run ...

A special point of interest for these researchers were the rates of prescribing of anti-obesity medication (AOM) among physicians treating adults versus children. This study was a secondary ...

Volume 17, Issue 4, on April 7, 2025, titled "Pharmacological recapitulation of the lean phenotype induced by the ...

Roll out of weight loss drugs in England could be dramatically sped up to millions of working age adults by making use of ...

And yet, the primary metric by which anti-obesity drugs are judged and distributed is weight. Originally, the FDA approved these medications for people with a BMI of 30 or above, or with a BMI of ...